Susan Percy Ivy
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Susan Percy Ivy has a total of 548 co-authors. Here are the top co-authors by number of shared publications:
- Elise C. Kohn
Cancer Therapy Evaluation Program, National Cancer Institute , Bethesda, MD
24 shared publications - Jan Handrick Beumer
Sidney Kimmel Comprehensive Cancer Center 11 Baltimore, MD
16 shared publications - Lawrence V. Rubinstein
Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD
15 shared publications - Biswajit Das
Molecular Characterization Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD
13 shared publications - Aman Chauhan
Division of Hematology and Oncology, University of California San Francisco, San Francisco, USA
12 shared publications - Aman Khurana
Department of Radiology, University of California, San Diego, San Diego, USA
12 shared publications
Latest Publications
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S4 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Pharmacokinetic profiles of triapine
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S4 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Pharmacokinetic profiles of triapine
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figure S5 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Survival plot stratified by AGGF1 and MEN1
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure S5 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Survival plot stratified by AGGF1 and MEN1
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Representativeness of study participants
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Representativeness of study participants
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S4 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Triapine geometric mean (SD) plasma pharmacokinetic parameters after PO administration
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S4 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Triapine geometric mean (SD) plasma pharmacokinetic parameters after PO administration
- Open Access
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S5 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Normalized exposure matrix from Sigminer
- 15 October 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S5 from Multicenter Phase I Study of Triapine in Combination with [177Lu]Lutetium-Dotatate in Patients with Well-Differentiated Neuroendocrine Tumors (ETCTN 10388)
Normalized exposure matrix from Sigminer